Adaptimmune Therapeutics ADR (NASDAQ:ADAP)
North American company
Share Price Chart
- Chart currently unavailable -
Market Info - ADAP
- Market Open Price0.00
- Previous Close0.00
- Volume-
- 52w Low/High-
- Last Trade Price0.00
- Bid/Ask Price0.00
Company Info - ADAP
- Market Cap$866.760m
- SymbolNASDAQ:ADAP
- IndustryHealthcare
- SectorBiotechnology
- Currency
- ISINUS00653A1079
Company Profile
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A10 T-cell therapy, NON-SMALL CELL LUNG CANCER, AFP SPEAR T-cell, MAGE-A4 SPEAR T-cell therapy and NY-ESO SPEAR T-cell for multiple cancer types.Adaptimmune Therapeutics PLC along with its subsidiaries is a clinical-stage biopharmaceutical company. It is engaged in novel cancer immunotherapy products based on its T-cell receptor platform.
Latest ADAP news
Currently there for this company. Visit our news hub for other news .